| Literature DB >> 24414197 |
Harald Schrem1, Moritz Kleine, Tim Oliver Lankisch, Alexander Kaltenborn, Lampros Kousoulas, Lea Zachau, Frank Lehner, Jürgen Klempnauer.
Abstract
BACKGROUND: Split liver transplantation is still discussed controversially. Utilization of split liver grafts has been declining since a change of allocation rules for the second graft abolished incentives for German centres to perform ex situ splits. We therefore analysed our long-term experiences with the first ex situ split liver transplant series worldwide.Entities:
Mesh:
Year: 2014 PMID: 24414197 PMCID: PMC7102172 DOI: 10.1007/s00268-013-2444-4
Source DB: PubMed Journal: World J Surg ISSN: 0364-2313 Impact factor: 3.352
Fig. 1Influence of the era on patient survival (p = 0.054; Kaplan–Meier analysis, log-rank test) (era 1 = 01.01.1987–31.12.1994, era 2 = 01.01.1995–31.12.2002, era 3 = 01.01.2003–31.12.2010). It is interesting to note that the survival has improved continuously from era to era with a growing number of performed transplants
Fig. 2Influence of the era on graft survival (p = 0.097; Kaplan–Meier analysis, log-rank test) (era 1 = 01.01.1987–31.12.1994, era 2 = 01.01.1995–31.12.2002, era 3 = 01.01.2003–31.12.2010). It is interesting to note that graft survival has improved continuously from era to era with a growing number of performed transplants without reaching statistical significance
Indications for liver transplantation in the study population and the leading causes of death following split liver transplantation
| Indications for split liver transplantation ( |
| % |
|---|---|---|
| Acute liver failure | 18 | 13.6 |
| Alcoholic cirrhosis | 3 | 2.4 |
| Autoimmune hepatitis | 2 | 1.6 |
| Budd Chiari syndrome | 2 | 1.6 |
| Cryptogenic cirrhosis | 6 | 4.5 |
| Hemangioendothelioma | 1 | 0.8 |
| Metabolic diseases | 3 | 2.4 |
| HBV-related cirrhosis | 11 | 5.3 |
| HCV-related cirrhosis | 7 | 8.3 |
| Hepatocellular carcinoma | 19 | 14.4 |
| Klatskin tumour | 1 | 0.8 |
| Liver adenoma | 3 | 2.4 |
| M. Osler/hemangioma | 1 | 0.8 |
| Neuroendocrine metastases | 2 | 1.6 |
| Primary/secondary biliary cirrhosis | 13 | 9.9 |
| Primary sclerosing cholangitis | 25 | 18.9 |
| Polycystic disease | 2 | 1.6 |
| Retransplantation due to chronic graft failure | 5 | 3.8 |
| Retransplantation due to acute graft failure | 7 | 5.3 |
| Total | 131 | 100 |
HBV hepatitis B, HCV hepatitis C, PNF primary nonfunction, ARDS acute respiratory distress syndrome
Transplanted segments, types of biliary reconstruction used, and T-drain usage frequency in this study
| Transplanted segments |
| % |
|---|---|---|
| Not specified | 2 | 1.5 |
| Segments 1–4 | 2 | 1.5 |
| Segments 2–4 | 8 | 6.1 |
| Segments 2+3 | 5 | 3.8 |
| Segments 4–8 | 9 | 6.9 |
| Segments 4–8+1 | 62 | 47.3 |
| Segments 5–8 | 34 | 26 |
| Segments 5–8+1 | 9 | 6.9 |
| Total | 131 | 100 |
Biliary complications, diagnostic methods used to detect them, as well as the time intervals between transplantation and the detection of the complication, the treatment modalities of biliary complications, and the time intervals between liver transplantation and the treatment of biliary complications within the study cohort
| Types of biliary complications ( | Diagnostic methods used to detect biliary complications | Median days from Tx to diagnosis | Treatment modality for biliary complications | Median days from Tx to treatment of biliary complication |
|---|---|---|---|---|
| Dehiscence of biliary anastomosis ( | Intraoperative ( HBSS ( ERC ( | 18 (3–37) | Reanastomosis of biliary duct ( ERC with stent ( Re-LTx ( | 18 (4–37) |
| Anastomotic stenosis ( | Sono ( ERC/PTCD ( | 211 (20–522) | Reanastomosis of biliary duct ( ERC with stent ( PTC with stent ( | 211 (20–522) |
| Biliary leakage from the resection plane ( | Intraoperative ( CT ( HBSS ( Sono ( MRCP ( | 6 (0–30) | Suture at the resection plane ( No specific treatment ( Interventional drainage ( | 6 (0–30) |
| Biliary leakage from a central bile duct ( | Intraoperative ( CT ( | 18 (2–19) | Suture at the central bile duct followed by reanastomosis of biliary duct ( Suture at the central bile duct followed by ERC with stent ( Interventional drainage (CT-guided) followed by Reanastomosis of biliary duct ( | Primary treatment 18 (2–19) Secondary treatment 23 (9–40) |
| Progressive ischaemic cholangiopathy ( | ERC/PTCD ( Biopsy ( | 260 (78–3,436) | Re-LTx ( PTC/ERC with stent ( No specific treatment ( | 456 (107–3,436) |
| Combined biliary complications: biliary leakage and anastomotic stenosis ( | CT ( HBSS ( Sono ( ERC ( | Primary diagnosis 15 (6–22) Secondary diagnosis: 1,851 (28–1,869) | Interventional drainage followed by ERC/PTC with stent ( Suture at the resection plane followed by reanastomosis of biliary duct ( Reanastomosis of biliary duct ( | Primary treatment 16 (6–22) Secondary treatment 963 (28–1,869) |
Five cases with progressive ischaemic cholangiopathy comprised two cases with ischemic-type biliary lesions (ITBL), two cases with secondary sclerosing cholangitis, and one case with CMV-associated chronic biliary tract destruction
HBSS hepatobiliary sequence scintigraphy, CT computed tomography, ERC endoscopic retrograde cholangiography, PTC percutaneous transhepatic cholangiography, PTCD percutaneous transhepatic cholangio-drainage, MRCP magnetic resonance cholangiopancreatogram
Types of biliary complications and their treatment as well as their respective statistical influence on patient and graft survival (Kaplan–Meier analysis with log-rank test)
| Types of biliary complications ( | No specific treatment ( | Interventional treatment ( | Surgical treatment ( | Influence of the type of biliary complication on patient survival | Influence of the type of biliary complication on graft survival |
|---|---|---|---|---|---|
| Biliary leakage ( | 2 | 6 | 16 | 0.109 | 0.244 |
| Anastomotic stenosis ( | – | 4 | 1 | 0.257 | 0.137 |
| Progressive ischaemic cholangiopathy ( | 1 | 2 | 2 | 0.838 | 0.245 |
| Biliary leakage and anastomotic stenosis ( | – | 4 | 3 | 0.309 | 0.186 |
| Patients ( | 3 (9 %) | 14 (40 %) | 20 (57.1 %) | ||
| Influence of the treatment modality on patient survival | 0.935 | 0.776 | 0.284 | n.a. | n.a. |
| Influence of the treatment modality on graft survival | 0.636 | 0.859 | 0.162 | n.a. | n.a. |
Two patients received both interventional and surgical treatment modalities for biliary complications
Details of 12 adult split liver retransplants (reLTX) in this series with observed patient and graft survival as well as the indications for the primary liver transplant procedures (LTX) and the retransplant procedures (reLTX) and the time intervals between LTX and reLTX in days
| Recipient sex | Time between LTX and reLTX (days) | Indication for primary LTX | Indication for reLTX | Transplanted segments (reLTX) | Death during the observation period | Patient survival (year) | Graft survival (year) |
|---|---|---|---|---|---|---|---|
| F | 47 | Cryptogenic cirrhosis | Biliary tract complications | 5–8 | Yes | 1.1 | 0.8 |
| F | 37 | PBC | Initial graft non-function | 1–4 | Yes | 9.0 | 0.1 |
| M | 1,159 | HBV HCV-related cirrhosis | Biliary tract complications | 4–8 | Yes | 0.1 | 0.1 |
| F | 10 | PSC | Biliary tract complications | 5–8+1 | Yes | 0.0 | 0.0 |
| F | 7 | HCC | Acute rejection | 5–8+1 | Yes | 0.2 | 0.2 |
| M | 666 | PSC | Chronic graft failure | 4–8+1 | No | 12.1 | 12.1 |
| F | 4,122 | Bylers disease | Chronic graft failure | 4–8+1 | No | 7.5 | 7.5 |
| F | 253 | HBV HDV-related cirrhosis | Biliary tract complications | 5–8+1 | No | 7.2 | 7.2 |
| M | 20 | Budd Chiari syndrome | Hepatic Artery thrombosis | 4–8+1 | No | 7.1 | 7.1 |
| M | 3 | HCC | Hepatic Artery thrombosis | 4–8+1 | Yes | 0.1 | 0.1 |
| M | 5,058 | Caroli syndrome | Chronic graft failure | 5–8 | No | 1.4 | 1.4 |
| M | 2 | Alcoholic cirrhosis | Initial graft nonfunction | 4–8+1 | Yes | 3.5 | 3.5 |
All primary transplants were performed with whole organ grafts
F female, M male, HCC hepatocellular carcinoma, HDV hepatitis D virus, PSC primary sclerosing cholangitis
Variables, their frequencies in our series, and their statistical influence on the occurrence of biliary complications after split liver transplantation (univariate logistic regression analysis, Chi square test) and on graft and patient survival
| Variables | Influence on biliary complications | Graft survival | Patient survival |
|---|---|---|---|
Cold ischemic time (min) Mean 705 min, median 722 min Range 104–1,262 min | n.s.a | n.s.a | n.s.a |
Warm ischemic time (min) Mean 40 min, median 38 min Range 18–112 min | n.s.a | n.s.a | n.s.a |
| HTK preservation ( | n.s.a | n.s.b | n.s.b |
| Hepatic artery thrombosis yes ( | n.s.a |
| n.s.b |
| Left-lateral graft yes ( | n.s.a | n.s.b | n.s.b |
| Hepaticojejunostomy yes ( | n.s.a | n.s.b | n.s.b |
| Postoperative bleeding complication yes ( | n.s.a | n.s.b | n.s.b |
| Retransplant case yes ( | n.s.a | n.s.a | n.s.a |
Units of intraoperatively transfused Red blood cells; mean 7, median 6 range 0–45 |
Exp(B) = 0.851 (95 % CI 0.761–0.951) | n.s.a |
|
Units of intraoperatively transfused Fresh-frozen plasma; mean 9, median 8 range 0–41 |
Exp(B) = 0.879 (95 % CI 0.803–0.961) | n.s.a | n.s.a |
Postoperative portal venous thrombosis did not occur in this series
n.s. not significant, HTK histidine-tryptophan-ketoglutarate organ preservation solution, UW University of Wisconsin organ preservation solution
a1-year survival Chi square test results
bKaplan–Meier analysis with log-rank test results
cLogistic regression analysis
Fig. 3Influence of observed biliary complications after split liver transplantation on hospital stay in days (p = 0.059; Kaplan–Meier analysis, log-rank test)